Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in…
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
December 06, 2024 16:35 ET | Source: BioAge Labs, Inc. Decision follows…
Theriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
December 05, 2024 08:00 ET | Source: Theriva Biologics, Inc. ROCKVILLE, Md.,…
Bharath Advanced Therapeutics (BAT) advancing Cancer treatment in India by setting new benchmarks in affordable and transformational care
HYDERABAD, India, Dec. 3, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT), as…
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate…
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (arimoclomol) for Treatment of Niemann-Pick Disease Type C
November 21, 2024 16:51 ET | Source: Zevra Therapeutics MIPLYFFA, the first…
Numab Therapeutics and Kaken Pharmaceutical Enter Collaborationand Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
Numab to receive R&D funding for the preclinical development of ND081 Kaken…
KFSHRCs New US Patent Opens New Frontiers for Breast Cancer Treatment
RIYADH, Saudi Arabia, Nov. 10, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist…
ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered…
ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered…